In this Medscape commentary, Dr. Scott Kopetz of MD Anderson unpacks the rising role of ctDNA in colorectal cancer. Unlike traditional risk factors, ctDNA offers a real-time snapshot of tumor biology with powerful prognostic value. From guiding adjuvant therapy decisions in stage 2 and 3 disease to detecting recurrence months before imaging, the test is reshaping how oncologists think about surveillance and trial design. With sensitivity still evolving and novel therapies on the horizon, is ctDNA about to become the new backbone of CRC management?
Trending
- How Guardant aims to expand cancer screening with a blood test (Medtech Dive)
- Endoscope manufacturer faces $1M lawsuit after demo explosion (Becker’s GI & Endoscopy)
- AI-Based Red Density Score Predicts Clinical Outcomes in Ulcerative Colitis (GI & Endoscopy News)
- Machine Learning Improves Accuracy of Inflammatory Bowel Disease Identification Beyond ICD-10 Codes (Houston Methodist)
- No Surprises Act payment dispute process booms to $22.4 billion cost in 4 years: study (Medical Economics)
- PENTAX Medical and MAGENTIQ EYE Expand Global Partnership to Advance AI-Assisted Colonoscopy Worldwide (PR Newswire)
- Following Their Own Advice? Medscape Gastroenterologist Mental Health & Well-Being Report 2026 (Medscape)
- In-person therapist-delivered hypnotherapy versus smartphone-based self-guided hypnotherapy in IBS: a multicentre three-armed randomised controlled trial (GUT)
